Bad news is good news, you just don’t know it yet.
Bio
Mike leads Armanino's Cannabis Tax group. A tax professional since 1989, he has significant experience in federal, state and local tax from both an accounting and legal perspective. He spent time with multiple Big 4 firms, including serving in KPMG’s Washington National Tax Office, and has worked with cannabis companies both large and small in California, Nevada, Oregon, Washington and Colorado.
He advises cannabis clients on a broad range of issues that affect the space, including mergers and acquisitions, loan structuring, and funding mechanisms from venture capital, private equity and investment banking. Mike provides guidance on cannabis technology, manufacturing, transportation and retail issues, and literally wrote the book on Cannabis Taxation for Thomson Reuters.
Mike is the contributing editor of Cannabis Taxation, a 250-page treatise for Thomson Reuters, discussing the 33 states that tax cannabis sales. He is a member of the California Society of Certified Public Accountants, the National Cannabis Industry Association and the California Cannabis Association, which nominated him for their CPA of the Year award for 2019. He holds a B.S. in mathematics and psychology from the University of Alabama, a J.D. from Cumberland Law, and a Masters of Tax Law from Emory Law School.
*Mike holds his interest in the firm through Goral & Associates, Inc.
Experience
I saw that cannabis was going to become a massive industry, similar to other regulated industries such as alcohol and tobacco. Federal, state and local governments were going to be expecting significant tax revenues generated by cannabis businesses. But traditional accountants were shying away from serving cannabis-related clients. There was an opportunity to become an expert in the field, so I made it my passion to learn about the law in all these other states — I even co-wrote a treatise about the 33 states that allow legal cannabis and their taxation mechanisms.
I think that cannabis, as an industry, is going to experience massive growth. Unlike alcohol and tobacco, cannabis has a real medical benefit that can't be ignored. We have this opioid crisis that's going on, and cannabis is a great alternative for those who use it for pain management, without the addictive and harmful side effects that opioids have. I think pharmaceutical companies will be conducting further research about the different compounds that are contained in cannabis and how they can be utilized in the healthcare space.